Michele Del Vecchio

12.6k total citations · 1 hit paper
169 papers, 5.1k citations indexed

About

Michele Del Vecchio is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Michele Del Vecchio has authored 169 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 129 papers in Oncology, 77 papers in Molecular Biology and 44 papers in Immunology. Recurrent topics in Michele Del Vecchio's work include Melanoma and MAPK Pathways (68 papers), Cancer Immunotherapy and Biomarkers (62 papers) and CAR-T cell therapy research (47 papers). Michele Del Vecchio is often cited by papers focused on Melanoma and MAPK Pathways (68 papers), Cancer Immunotherapy and Biomarkers (62 papers) and CAR-T cell therapy research (47 papers). Michele Del Vecchio collaborates with scholars based in Italy, United States and Australia. Michele Del Vecchio's co-authors include Emilio Bajetta, Andrea Anichini, Paola Queirolo, Paolo A. Ascierto, Giorgio Parmiani, Vanna Chiarion‐Sileni, Lorenza Di Guardo, Stefania Canova, Michael T. Lotze and Amy Wesa and has published in prestigious journals such as The Lancet, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Michele Del Vecchio

161 papers receiving 5.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial

2017 482 citations Caroline Robert, Jean‐Jacques Grob et al. profile →

Peers

Countries citing papers authored by Michele Del Vecchio

Since Specialization

Citations

This map shows the geographic impact of Michele Del Vecchio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michele Del Vecchio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michele Del Vecchio more than expected).

Fields of papers citing papers by Michele Del Vecchio

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michele Del Vecchio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michele Del Vecchio. The network helps show where Michele Del Vecchio may publish in the future.

Co-authorship network of co-authors of Michele Del Vecchio

This figure shows the co-authorship network connecting the top 25 collaborators of Michele Del Vecchio. A scholar is included among the top collaborators of Michele Del Vecchio based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michele Del Vecchio. Michele Del Vecchio is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	1609P Final, 9-year results from the CheckMate 238 phase III trial of adjuvant nivolumab vs ipilimumab in resected stage IIIB–C or IV melanoma 2025 ·Annals of Oncology ·Paolo A. Ascierto, Michele Del Vecchio, Barbara Merelli, Helen Gogas, Ana Arance, Stéphane Dalle, C. Lance Cowey, Michael Schenker, (unknown), Jacopo Pigozzo, Iván Márquez‐Rodas, (unknown), Anna Maria Di Giacomo, Mark R. Middleton, (unknown), Luis de la Cruz‐Merino, (unknown), (unknown), Margarita Askelson, James Larkin	0
2	Triplet combination treatments with pembrolizumab (pembro) for anti–PD-(L)1–refractory advanced melanoma: Preliminary results of the phase 1/2 KEYMAKER-U02A study. 2024 ·Journal of Clinical Oncology ·Reinhard Dummer, Jean‐Jacques Grob, Caroline Robert, Ronnie Shapira‐Frommer, Célèste Lebbé, Paolo A. Ascierto, Stéphane Dalle, Omid Hamid, Nicolás Meyer, Muhammad Adnan Khattak, Andrew Hill, Jonathan Cohen, Giuseppe Curigliano, Anna Maria Di Giacomo, Michele Del Vecchio, Sekwon Jang, (unknown), Xuan Peng, Scott J. Diede, Georgina V. Long	2
3	Combination or sequence of vemurafenib, cobimetinib, and atezolizumab in high-risk, resectable melanoma (NEO-TIM): Primary results. 2024 ·Journal of Clinical Oncology ·Paolo A. Ascierto, Pietro Quaglino, Francesco Spagnolo, Massimo Guidoboni, Michele Del Vecchio, Michele Guida, Ketty Peris, Luisa Fioretto, Virginia Caliendo, Riccardo Marconcini, Paola Queirolo, Corrado Caracò, Simone Mocellin, Maria Grazia Vitale, Domenico Mallardo, Diana Giannarelli, Miriam Paone, Claudia Trojaniello, Daniela Massi, Vanna Chiarion‐Sileni	2
4	Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study. 2023 ·Journal of Clinical Oncology ·Jason J. Luke, Paolo A. Ascierto, Muhammad Adnan Khattak, Luis de la Cruz‐Merino, Michele Del Vecchio, Piotr Rutkowski, Francesco Spagnolo, Jacek Mackiewicz, Vanna Chiarion‐Sileni, John M. Kirkwood, Caroline Robert, Jean‐Jacques Grob, Federica De Galitiis, Dirk Schadendorf, Matteo S. Carlino, (unknown), Mizuho Fukunaga‐Kalabis, Clemens Krepler, Alexander M.M. Eggermont, Georgina V. Long	7
5	Association of biomarkers (BMs) with efficacy of adjuvant nivolumab (NIVO) vs placebo (PBO) in patients with resected stage IIB/C melanoma (CA209-76K). 2023 ·Journal of Clinical Oncology ·Georgina V. Long, John M. Kirkwood, Christoph Höeller, Jean‐Jacques Grob, Jeffrey S. Weber, Janis M. Taube, Peter Mohr, Alexander Christopher Jonathan Van Akkooi, Carmen Loquai, Caroline Dutriaux, Vanna Chiarion‐Sileni, Daniel J. Tenney, Sonia Dolfi, Hao Tang, Corey Ritchings, Maurice Lobo, Federico Campigotto, Wenjia Wang, Brian Gastman, Michele Del Vecchio	8
6	Association of circulating tumor DNA kinetics with disease recurrence in patients with stage IIIB/C/IV melanoma treated with adjuvant immunotherapy in Checkmate 238. 2023 ·Journal of Clinical Oncology ·(unknown), Jennifer Wiggins, (unknown), (unknown), Hao Tang, (unknown), (unknown), Keyur Desai, Sonia Dolfi, Daniel J. Tenney, Paolo A. Ascierto, James Larkin, Michele Del Vecchio, Jeffrey S. Weber, David Polsky	3
7	1084MO Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial 2023 ·Annals of Oncology ·Anna Maria Di Giacomo, (unknown), Michele Del Vecchio, Pier Francesco Ferrucci, Michele Guida, Pietro Quaglino, Massimo Guidoboni, Paolo Marchetti, (unknown), Giovanni Amato, Alessia Covre, Roberto Camerini, Luana Calabrò, Monica Valente, Mario Mandalà, Diana Giannarelli, Michele Maio	2
8	Gut Microbiota, Metabolome, and Body Composition Signatures of Response to Therapy in Patients with Advanced Melanoma 2023 ·International Journal of Molecular Sciences ·(unknown), Federica D’Amico, Marco Fabbrini, Luigi Mariani, Sabina Sieri, (unknown), Lorenza Di Guardo, Michele Del Vecchio, Andrea Anichini, Roberta Mortarini, Francesco Sgambelluri, Giuseppe Celano, (unknown), Maria De Angelis, Patrizia Brigidi, Cecilia Gavazzi, Silvia Turroni	10
9	Flood Susceptibility Mapping Using a Deep Neural Network Model: The Case Study of Southern Italy 2022 ·SHILAP Revista de lepidopterología ·(unknown), Michele Del Vecchio, (unknown), (unknown), (unknown), Salvatore Manfreda, Giovanni Menduni, (unknown)	7
10	Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases 2021 ·Clinical Cancer Research ·Anna Maria Di Giacomo, Vanna Chiarion‐Sileni, Michele Del Vecchio, Pier Francesco Ferrucci, Michele Guida, Pietro Quaglino, Massimo Guidoboni, Paolo Marchetti, Ornella Cutaia, Giovanni Amato, Alessia Covre, Roberto Camerini, Luana Calabrò, Monica Valente, Diana Giannarelli, Mario Mandalà, Michele Maio	41
11	A Zero-Order Flood Damage Model for Regional-Scale Quick Assessments 2021 ·Water ·(unknown), (unknown), (unknown), (unknown), Michele Del Vecchio, Giovanni Menduni, Daniela Molinari, (unknown)	3
12	Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy) 2021 ·Targeted Oncology ·Massimo Aglietta, Vanna Chiarion‐Sileni, Paolo Fava, Massimo Guidoboni, Roberta Depenni, Alessandro Marco Minisini, Francesca Consoli, Paolo A. Ascierto, Gaetana Rinaldi, Maria Banzi, Riccardo Marconcini, (unknown), Virginia Ferraresi, Marco Tucci, Giuseppe Tonini, Re G, Michele Guida, Michele Del Vecchio, Ilaria Marcon, Paola Queirolo	5
13	Toxicity of carbon ion radiotherapy and immune checkpoint inhibitors in advanced melanoma 2021 ·Radiotherapy and Oncology ·Stefano Cavalieri, Sara Ronchi, Amelia Barcellini, Maria Bonora, Barbara Vischioni, Viviana Vitolo, (unknown), Michele Del Vecchio, Lisa Licitra, Ester Orlandi	14
14	Investigating the role of immunotherapy in advanced/recurrent female genital tract melanoma: a preliminary experience 2019 ·Journal of Gynecologic Oncology ·Alice Indini, Lorenza Di Guardo, Carolina Cimminiello, Domenica Lorusso, Francesco Raspagliesi, Michele Del Vecchio	33
15	Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma 2019 ·Nature Medicine ·Paolo A. Ascierto, Pier Francesco Ferrucci, Rosalie Fisher, Michele Del Vecchio, Victoria Atkinson, Henrik Schmidt, Jacob Schachter, Paola Queirolo, Georgina V. Long, Anna Maria Di Giacomo, Inge Marie Svane, Michal Lotem, Gil Bar‐Sela, Félix Couture, Bijoyesh Mookerjee, Razi Ghori, Nageatte Ibrahim, Blanca Homet Moreno, Antoni Ribas	219
16	Aggiornamento AACR dei dati di sopravvivenza a 5 anni, efficacia e sicurezza a lungo termine in pazienti con melanoma metastatico avanzato che ricevono mono-immunoterapia con nivolumab 2016 ·Recenti Progressi in Medicina ·Michele Del Vecchio	3
17	T Lymphocytes Redirected against the Chondroitin Sulfate Proteoglycan-4 Control the Growth of Multiple Solid Tumors both In Vitro and In Vivo 2013 ·Clinical Cancer Research ·Claudia Geldres, Barbara Savoldo, Valentina Hoyos, Ignazio Caruana, Ming Zhang, Eric Yvon, Michele Del Vecchio, Chad J. Creighton, Michael Ittmann, Soldano Ferrone, Gianpietro Dotti	80
18	Bevacizumab plus Fotemustine as First-line Treatment in Metastatic Melanoma Patients: Clinical Activity and Modulation of Angiogenesis and Lymphangiogenesis Factors 2010 ·Clinical Cancer Research ·Michele Del Vecchio, Roberta Mortarini, Stefania Canova, Lorenza Di Guardo, Nicola Pimpinelli, M. R. Sertoli, Davide Bedognetti, Paola Queirolo, (unknown), Tania Perrone, Emilio Bajetta, Andrea Anichini	44
19	Immunotherapy of Metastatic Melanoma Using Genetically Engineered GD2-Specific T cells 2009 ·Clinical Cancer Research ·Eric Yvon, Michele Del Vecchio, Barbara Savoldo, Valentina Hoyos, Aurélie Dutour, Andrea Anichini, Gianpietro Dotti, Malcolm K. Brenner	113
20	Primary Uterine Cervix Melanoma Resembling Malignant Peripheral Nerve Sheath Tumor: A Case Report 2008 ·International Journal of Gynecological Pathology ·Sara Pusceddu, Emilio Bajetta, Roberto Buzzoni, Maria Luisa Carcangiu, Marco Platania, Michele Del Vecchio, Antonino Ditto	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact